Evidence map›Paper›PMID 34243716›Full record

ArticleBMC infectious diseases2021

Transmitted drug resistance to Tenofovir/Emtricitabine among persons with newly diagnosed HIV infection in Shenyang city, Northeast China from 2016 to 2018.

Zhen Wang, Bin Zhao, Minghui An, Wei Song, Xue Dong, Xin Li, Lu Wang, Lin Wang, Wen Tian, Haibo Ding and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 58% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Zhen Wang *National Clinical Research Center for Laboratory Medicine, NHC Key Laboratory of AIDS Immunology (China Medical University), The First Affiliated Hospital of China Medical University, No 155, Nanjing North Street, Heping District, Shenyang, 110001, Liaoning Province, China.
Bin Zhao *National Clinical Research Center for Laboratory Medicine, NHC Key Laboratory of AIDS Immunology (China Medical University), The First Affiliated Hospital of China Medical University, No 155, Nanjing North Street, Heping District, Shenyang, 110001, Liaoning Province, China.
Minghui AnNational Clinical Research Center for Laboratory Medicine, NHC Key Laboratory of AIDS Immunology (China Medical University), The First Affiliated Hospital of China Medical University, No 155, Nanjing North Street, Heping District, Shenyang, 110001, Liaoning Province, China.
Wei SongDepartment of Food Safety and Nutrition, Shenyang Center for Health Service and Administrative Law Enforcement (Shenyang Center for Disease Control and Prevention), Shenyang, 110031, China.
Xue DongDepartment of Food Safety and Nutrition, Shenyang Center for Health Service and Administrative Law Enforcement (Shenyang Center for Disease Control and Prevention), Shenyang, 110031, China.
Xin LiDepartment of Food Safety and Nutrition, Shenyang Center for Health Service and Administrative Law Enforcement (Shenyang Center for Disease Control and Prevention), Shenyang, 110031, China.
Lu WangDepartment of Food Safety and Nutrition, Shenyang Center for Health Service and Administrative Law Enforcement (Shenyang Center for Disease Control and Prevention), Shenyang, 110031, China.
Lin WangNational Clinical Research Center for Laboratory Medicine, NHC Key Laboratory of AIDS Immunology (China Medical University), The First Affiliated Hospital of China Medical University, No 155, Nanjing North Street, Heping District, Shenyang, 110001, Liaoning Province, China.
Wen TianNational Clinical Research Center for Laboratory Medicine, NHC Key Laboratory of AIDS Immunology (China Medical University), The First Affiliated Hospital of China Medical University, No 155, Nanjing North Street, Heping District, Shenyang, 110001, Liaoning Province, China.
Haibo DingNational Clinical Research Center for Laboratory Medicine, NHC Key Laboratory of AIDS Immunology (China Medical University), The First Affiliated Hospital of China Medical University, No 155, Nanjing North Street, Heping District, Shenyang, 110001, Liaoning Province, China.
Xiaoxu HanNational Clinical Research Center for Laboratory Medicine, NHC Key Laboratory of AIDS Immunology (China Medical University), The First Affiliated Hospital of China Medical University, No 155, Nanjing North Street, Heping District, Shenyang, 110001, Liaoning Province, China. hanxiaoxu@cmu.edu.cn.ORCID http://orcid.org/0000-0003-1427-8428
Chinese Academy of Medical Sciences & Peking Union Medical College · CNShenyang Center for Disease Control and Prevention · CNLiaoning University · CN

Funding

Mega-Projects of National Science Research for the 13th Five-Year Plan 2018ZX10721102
6 · The paper itself

Abstract

backgroundTo assess transmitted drug resistance (TDR) to tenofovir (TDF)/emtricitabine (FTC), using as pre-exposure prophylaxis, among newly diagnosed human immunodeficiency virus-1 (HIV-1)-infected residents in Shenyang city, northeast China.

methodsDemographic and epidemiological information of all newly diagnosed HIV-1 infected residents in Shenyang city from 2016 to 2018 were anonymously collected from the local HIV epidemic database. HIV-1 pol sequences were amplified from RNA in cryopreserved plasma samples and sequenced directly. Viral subtypes were inferred with phylogenetic analysis and drug resistance mutations (DRMs) were determined according to the Stanford HIVdb algorithm. Recent HIV infection was determined with HIV Limiting Antigen avidity electro immunoassay.

resultsA total of 2176 sequences (92.4%, 2176/2354) were obtained; 70.9% (1536/2167) were CRF01_AE, followed by CRF07_BC (18.0%, 391/2167), subtype B (4.7%, 102/2167), other subtypes (2.6%, 56/2167), and unique recombinant forms (3.8%, 82/2167). The prevalence of TDR was 4.9% (107/2167), among which, only 0.6% (13/2167) was resistance to TDF/FTC. Most of these subjects had CRF01_AE strains (76.9%, 10/13), were unmarried (76.9%, 10/13), infected through homosexual contact (92.3%, 12/13), and over 30 years old (median age: 33). The TDF/FTC DRMs included K65R (8/13), M184I/V (5/13), and Y115F (2/13). Recent HIV infection accounted for only 23.1% (3/13). Most cases were sporadic in the phylogenetic tree, except two CRF01_AE sequences with K65R (Bootstrap value: 99%).

conclusionsThe prevalence of TDR to TDF/FTC is low among newly diagnosed HIV-infected cases in Shenyang, suggesting that TDR may have little impact on the protective effect of the ongoing CROPrEP project in Shenyang city.

Indexed as

Drug Resistance, ViralAdolescentAdultAgedAged, 80 and overAnti-HIV AgentsChildChild, PreschoolChinaEmtricitabineEpidemicsFemaleGenotypeHIV-1HIV InfectionsHumansAnti-HIV AgentsEmtricitabineReverse Transcriptase InhibitorsTenofovirHIV-1Pre-exposure prophylaxisTransmitted drug resistance

Identifiers

PMID34243716
PMCPMC8268309
OpenAlexW3180134571

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.